MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial.
Wolfgang Wick
Consultant or Advisory Role - Antisense Pharma; Magforce; MSD; Roche
Honoraria - MSD; Roche
Research Funding - Apogenix; Boehringer Ingelheim; Lilly; MSD
Christoph Meisner
No relevant relationships to disclose
Michael Platten
Honoraria - Merck Serono
Research Funding - Bayer Schering Pharma; Merck Serono
Matthias Simon
No relevant relationships to disclose
Guido Nikkhah
No relevant relationships to disclose
Kirstin Papsdorf
No relevant relationships to disclose
Michael Sabel
Consultant or Advisory Role - Magforce
Christian Braun
No relevant relationships to disclose
Guido Reifenberger
Consultant or Advisory Role - MSD
Honoraria - MSD
Michael Weller
Consultant or Advisory Role - Merck Serono; MSD; Roche
Honoraria - Merck Serono; Merck Sharp & Dohme; Roche
Research Funding - Merck Serono